Total Payments
$373,852
2024 Payments
$24,987
Companies
61
Transactions
2,256
Medicare Patients
7,643
Medicare Billing
$1.3M
Payment Breakdown by Category
Other$298,811 (79.9%)
Food & Beverage$57,785 (15.5%)
Consulting$8,829 (2.4%)
Travel$8,255 (2.2%)
Education$113.23 (0.0%)
Gifts$59.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $290,486 | 169 | 77.7% |
| Food and Beverage | $57,785 | 1,999 | 15.5% |
| Consulting Fee | $8,829 | 3 | 2.4% |
| Honoraria | $8,325 | 5 | 2.2% |
| Travel and Lodging | $8,255 | 62 | 2.2% |
| Education | $113.23 | 17 | 0.0% |
| Gift | $59.40 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $117,645 | 347 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $93,564 | 265 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $79,360 | 204 | $0 (2024) |
| Shire North American Group Inc | $34,383 | 85 | $0 (2019) |
| Horizon Therapeutics plc | $11,969 | 71 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $11,600 | 66 | $0 (2023) |
| Novo Nordisk Inc | $3,218 | 157 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,337 | 117 | $0 (2024) |
| Amneal Pharmaceuticals LLC | $1,993 | 75 | $0 (2024) |
| Mannkind Corporation | $1,680 | 96 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,987 | 275 | Amgen Inc. ($19,543) |
| 2023 | $24,899 | 272 | Horizon Therapeutics plc ($11,057) |
| 2022 | $11,145 | 240 | Amgen Inc. ($6,849) |
| 2021 | $22,065 | 251 | Amgen Inc. ($13,960) |
| 2020 | $35,870 | 260 | AstraZeneca Pharmaceuticals LP ($16,110) |
| 2019 | $74,369 | 341 | Amgen Inc. ($22,111) |
| 2018 | $88,638 | 308 | SANOFI-AVENTIS U.S. LLC ($37,599) |
| 2017 | $91,879 | 309 | SANOFI-AVENTIS U.S. LLC ($30,503) |
All Payment Transactions
2,256 individual payment records from CMS Open Payments — Page 1 of 91
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Diabetes | ||||||
| 12/19/2024 | Chiesi USA, Inc. | MYCAPSSA (Drug) | Food and Beverage | Cash or cash equivalent | $28.00 | General |
| Category: ACROMEGALY | ||||||
| 12/19/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 12/18/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $20.30 | General |
| Category: Biological | ||||||
| 12/17/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $21.11 | General |
| Category: Endocrinology | ||||||
| 12/17/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $15.43 | General |
| Category: DIABETES MEDICINE | ||||||
| 12/13/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 12/12/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $28.15 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/11/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/10/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/09/2024 | Almatica Pharma LLC | TERIPARATIDE (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: OSTEOPOROSIS | ||||||
| 12/05/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $27.52 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: DIABETES | ||||||
| 12/04/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/03/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.05 | General |
| Category: DIABETES | ||||||
| 12/02/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: Obesity | ||||||
| 11/22/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: Diabetes | ||||||
| 11/21/2024 | Chiesi USA, Inc. | MYCAPSSA (Drug) | Food and Beverage | Cash or cash equivalent | $29.93 | General |
| Category: ACROMEGALY | ||||||
| 11/21/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 11/21/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 11/20/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: NEUROSCIENCE | ||||||
| 11/20/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: Endocrinology | ||||||
| 11/19/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $27.43 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/19/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: DIABETES MEDICINE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,661 | 4,955 | $544,253 | $307,281 |
| 2022 | 11 | 1,732 | 4,961 | $462,360 | $298,966 |
| 2021 | 12 | 2,075 | 6,402 | $597,776 | $394,012 |
| 2020 | 13 | 2,175 | 6,026 | $583,258 | $346,112 |
Total Patients
7,643
Total Services
22,344
Medicare Billing
$1.3M
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 388 | 1,174 | $224,133 | $130,562 | 58.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 176 | 1,222 | $155,194 | $83,825 | 54.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 330 | 922 | $79,526 | $45,799 | 57.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 181 | 211 | $42,968 | $23,858 | 55.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 337 | 936 | $12,289 | $7,862 | 64.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 43 | 43 | $10,825 | $6,286 | 58.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 56 | 155 | $7,734 | $4,582 | 59.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 25 | $4,718 | $2,580 | 54.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 12 | 14 | $1,765 | $1,115 | 63.1% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 123 | 253 | $5,100 | $812.13 | 15.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 391 | 1,119 | $192,100 | $124,663 | 64.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 209 | 1,364 | $126,840 | $85,811 | 67.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 333 | 867 | $64,678 | $42,849 | 66.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 200 | 238 | $42,190 | $28,558 | 67.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 29 | 29 | $6,496 | $4,275 | 65.8% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 51 | 140 | $6,356 | $4,267 | 67.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 31 | $4,133 | $2,796 | 67.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 340 | 865 | $10,518 | $2,563 | 24.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $3,109 | $2,101 | 67.6% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 134 | 283 | $5,696 | $915.89 | 16.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 12 | 13 | $242.58 | $167.83 | 69.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 322 | 2,403 | $223,311 | $153,286 | 68.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 392 | 1,127 | $193,168 | $128,907 | 66.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 316 | 376 | $66,654 | $45,229 | 67.9% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 351 | 909 | $67,811 | $44,031 | 64.9% |
About Dr. Matvey Brokhin, MD
Dr. Matvey Brokhin, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/12/2007. The National Provider Identifier (NPI) number assigned to this provider is 1770615064.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matvey Brokhin, MD has received a total of $373,852 in payments from pharmaceutical and medical device companies, with $24,987 received in 2024. These payments were reported across 2,256 transactions from 61 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($290,486).
As a Medicare-enrolled provider, Brokhin has provided services to 7,643 Medicare beneficiaries, totaling 22,344 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism|Internal Medicine|Endocrinology, Diabetes & Metabolism
- Location Brooklyn, NY
- Active Since 03/12/2007
- Last Updated 08/03/2011
- Taxonomy Code 207RE0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1770615064
Products in Payments
- Repatha (Biological) $102,483
- FARXIGA (Drug) $75,567
- SOLIQUA (Drug) $38,254
- NATPARA (Drug) $31,128
- TOUJEO (Drug) $19,485
- PRALUENT (Drug) $19,218
- TEPEZZA (Biological) $13,477
- TEPEZZA (Drug) $11,868
- SOLIQUA 100/33 (Drug) $11,336
- PRALUENT (Biological) $7,532
- PRALUENT ALIROCUMAB INJECTION (Biological) $3,890
- SOLIQUA 100/33 (Biological) $3,735
- BYDUREON (Drug) $3,632
- NATPARA (PARATHYROID HORMONE) (Drug) $3,232
- JARDIANCE (Drug) $2,482
- UNITHROID (Drug) $2,065
- AFREZZA (Drug) $1,680
- Vascepa (Drug) $1,606
- TOUJEO (Biological) $1,469
- TRULANCE (Drug) $892.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Brooklyn
Dr. Matin Sharafatkhah, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $437,076
Endocrinology, Diabetes & Metabolism $437,076
Dr. Robert Silver, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $354,536
Endocrinology, Diabetes & Metabolism $354,536
Alexander Perkelvald, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $343,784
Endocrinology, Diabetes & Metabolism $343,784
Dr. Iraklii Buziashvili, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $122,903
Endocrinology, Diabetes & Metabolism $122,903
Dr. Saka Kazeem, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $23,364
Endocrinology, Diabetes & Metabolism $23,364
Dr. Miroslawa Kudej, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $17,117
Endocrinology, Diabetes & Metabolism $17,117